Organigram Global Inc. (OGI) Stock Price & How to Invest
Last updated July 2026
Short answer
You can invest in Organigram Global (OGI) by buying shares or fractional shares at any major US broker, through a cannabis-sector ETF that holds it, or as one holding in a thematic basket. Organigram is a Canadian licensed cannabis producer (renamed from Organigram Holdings in 2025) that grows, processes, and sells recreational and medical cannabis and, increasingly, cannabis and hemp-derived beverages and edibles. It is Canada's largest recreational cannabis company by market share, and its story is now closely tied to British American Tobacco (BAT), which has invested heavily and holds a large minority stake. The single most important thing to understand is that this is a still-maturing, competitive, and historically unprofitable industry, and that cannabis remains federally illegal in the United States, so OGI is a higher-risk, sector-driven stock rather than a steady compounder.
OGI stock price
As of 2026-07-14, Organigram Global Inc. (OGI) last closed at $0.8704, down 41.2% over the past year. Over the past 52 weeks it has traded between $0.8704 and $2.11.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Organigram Global Inc.'s investor relations page. Walnut is informational, not investment advice.
What does Organigram Global Inc. (OGI) do?
Organigram Global Inc. is a Canadian cannabis company that cultivates, processes, and sells adult-use and medical cannabis products, including dried flower, pre-rolls, vapes, edibles, and a fast-growing lineup of cannabis and hemp-derived beverages. It changed its name from Organigram Holdings to Organigram Global in 2025, keeping the ticker OGI, and trades on both the Nasdaq and the Toronto Stock Exchange (it reports in Canadian dollars). By recreational market share it is Canada's number-one cannabis company, and it has been expanding beyond Canada into international medical markets and the US hemp-derived THC beverage space.
Two forces define the current story. First, British American Tobacco (BAT) has made a series of investments totaling roughly C$124.6 million across three tranches through early 2025, and as of April 2026 held about 42.2 million common shares (around 29.9% of the company) plus a large block of preferred shares. This gives Organigram a deep-pocketed strategic backer and a cash-rich balance sheet with little debt. Second, growth has accelerated on acquisitions and expansion: the December 2024 purchase of Motif Labs added scale and cost synergies, the Collective Project deal opened a path into US and Canadian THC beverages, and a roughly C$21 million investment in Germany's Sanity Group extended its European reach. In the first quarter of fiscal 2026 (reported February 2026) Organigram posted gross revenue of about C$97 million, up roughly 46% year over year, net revenue near C$63.5 million, international revenue around C$5 million, and adjusted EBITDA of about C$5.3 million, a sharp improvement, even as the broader cannabis industry stays crowded and price-competitive.
What's driving Organigram Global Inc. (OGI)?
1. British American Tobacco partnership
BAT's roughly C$124.6 million of investment and its near-30% stake give Organigram a well-capitalized strategic backer, a cash cushion, and a partner with global distribution and next-generation-products expertise. The relationship funds expansion and lends credibility, but it also concentrates influence in one large shareholder whose priorities may not always align with those of minority holders.
2. Scale, Motif synergies, and market share
Organigram is Canada's number-one recreational cannabis company by market share, and the December 2024 Motif Labs acquisition added manufacturing scale and cost synergies (raised to around C$15 million). Higher volumes and integration savings have lifted adjusted gross margins and helped turn adjusted EBITDA sharply positive, though holding share in a fragmented, discount-driven market takes continual investment.
3. International and beverage expansion
Growth is increasingly coming from beyond Canadian flower: international sales (roughly C$5 million in Q1 FY2026, up about 51%) are rising via medical markets and the C$21 million Sanity Group stake in Germany, while the Collective Project acquisition takes Organigram into fast-growing US and Canadian hemp-derived THC beverages, reaching around 11 US states. These lanes diversify revenue but are early-stage and face their own regulatory uncertainty.
4. Balance sheet and path to durable profit
Organigram carries a healthy cash position and negligible debt, giving it room to invest while many peers are stretched. The key watch item is converting revenue growth into consistent operating profit and free cash flow: reported net income has swung widely and has at times been boosted by non-cash fair-value and one-time items, so adjusted EBITDA and cash generation are better gauges of underlying progress than headline profit.
What are the risks to Organigram Global Inc. (OGI)?
The overarching risk is that cannabis remains federally illegal in the United States, which locks Organigram out of the largest potential market, limits access to US banking and exchanges for the plant-touching business, and caps the sector's valuations. The Canadian and global cannabis industry is oversupplied and intensely price-competitive, so pricing pressure and heavy excise taxes squeeze margins even as volumes grow. Profitability has been inconsistent, and reported earnings can be distorted by non-cash fair-value changes on biological assets and investments. The large BAT stake concentrates ownership and influence, and future financings or share issuance could dilute existing holders. Regulatory change, international-market execution, and the early, unproven economics of the THC-beverage push all add uncertainty, and cannabis stocks as a group tend to be volatile and sentiment-driven.
How is Organigram Global Inc. (OGI) valued? (approximate, Jul 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Organigram Global Inc.'s investor relations page or your broker.
- Gross revenue (Q1 FY2026, reported Feb 2026): Approximately C$97 million, up roughly 46% year over year (figures in Canadian dollars)
- Net revenue (Q1 FY2026): Approximately C$63.5 million, up roughly 49% year over year
- Adjusted EBITDA (Q1 FY2026): Approximately C$5.3 million, a sharp improvement (up roughly 273%) year over year
- International revenue (Q1 FY2026): Approximately C$5 million, up about 51% year over year
- Balance sheet: Strong cash position with negligible debt, aided by British American Tobacco's roughly C$124.6 million of aggregate investment
- BAT ownership: About 42.2 million common shares (approximately 29.9%) plus a large preferred-share block, as of April 2026
Figures are approximate, reported in Canadian dollars, drawn from Organigram's fiscal 2026 reporting, and tied to the asOf date; verify live numbers before acting. For a cannabis company, revenue growth, adjusted EBITDA, and cash are more telling than headline net income, which can swing on non-cash fair-value adjustments to biological assets and investments. Cannabis stocks also trade heavily on sector sentiment and regulatory headlines, so traditional earnings multiples are of limited use here.
Who competes with Organigram Global Inc. (OGI)?
Canadian licensed producers
Organigram's most direct rivals are other large Canadian licensed producers such as Tilray, Canopy Growth, Aurora Cannabis, and Cronos Group. They compete for shelf space and market share in a crowded, discount-driven domestic market, and several, like Organigram, are pushing internationally and into adjacent products such as beverages to diversify away from commoditized flower.
US multi-state operators
US multi-state operators like Green Thumb Industries, Curaleaf, and Trulieve operate in state-legal US markets that Organigram cannot fully enter while cannabis is federally illegal. They are not head-to-head competitors today, but they represent the large US opportunity that reform could open, and they compete for the same cannabis-sector investment dollars.
Beverage, hemp, and tobacco-adjacent players
In hemp-derived THC beverages and next-generation products, Organigram faces a growing field of beverage and hemp brands, plus the strategic reach of tobacco and consumer-goods companies moving into cannabis. Its own BAT backing places it within that tobacco-adjacent group, but it must still win consumers against fast-moving beverage startups and established drinks brands.
How to invest in Organigram Global Inc. (OGI)
There are three common ways to get OGI exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so OGI sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where OGI fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Organigram Global Inc. (OGI)
Organigram is Canada's top cannabis producer by share, growing fast through the Motif acquisition and international expansion, and backed by a large BAT investment and a strong cash position. But it operates in an oversupplied, price-competitive industry where profits are inconsistent, and US federal cannabis prohibition caps its largest potential market.
Build a basket around OGI with Walnut
Use Organigram Global Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is OGI a good stock to buy right now?
+
That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is that Organigram is Canada's top cannabis producer by share, is growing revenue fast through the Motif acquisition and international expansion, and has a cash-rich balance sheet backed by British American Tobacco. The bear case is that cannabis is federally illegal in the US (capping the biggest market), the industry is oversupplied and price-competitive, profits have been inconsistent, and the sector is volatile and sentiment-driven. Weigh both against your own portfolio.
What does Organigram actually do?
+
Organigram Global is a Canadian licensed cannabis producer that grows, processes, and sells adult-use and medical cannabis, including dried flower, pre-rolls, vapes, and edibles, plus a growing lineup of cannabis and hemp-derived beverages. It sells across Canadian provinces, exports to international medical markets, and, through the Collective Project acquisition, sells hemp-derived THC beverages in parts of the US. It reports its financials in Canadian dollars.
What is the British American Tobacco stake in Organigram?
+
British American Tobacco (BAT) has invested roughly C$124.6 million in Organigram across three tranches through early 2025. As of April 2026, BAT held about 42.2 million common shares, around 29.9% of the company, plus a large block of preferred shares. The investment gives Organigram cash and a strategic partner with global reach, while making BAT its most influential shareholder.
Why did Organigram change its name to Organigram Global?
+
Organigram Holdings rebranded to Organigram Global in 2025 (with the change taking effect around March 31, 2025) to reflect its expansion beyond Canada into international medical markets and the US and European cannabis and hemp-beverage spaces. The rebrand included a new logo and identity, but the Nasdaq and TSX ticker stayed the same at OGI.
Does Organigram pay a dividend?
+
Organigram has not been a dividend payer. Like most cannabis companies, it reinvests cash into growth, acquisitions, and international expansion rather than returning it to shareholders, and its profitability has been inconsistent. Investors in OGI are generally betting on share-price appreciation from the cannabis theme, not on income. Always check the latest company disclosures before assuming any payout.
How does US cannabis law affect Organigram?
+
Cannabis remains illegal at the US federal level, which prevents Organigram from selling plant-touching cannabis products across most of the US market and limits access to US banking and services for that business. It can participate in US hemp-derived THC beverages where state rules allow. Federal reform could expand its opportunity, but the timing and outcome are uncertain, and the prohibition is a major overhang on the whole sector.
Why are Organigram's profits so inconsistent?
+
Cannabis companies often report volatile net income because accounting rules require them to mark biological assets and certain investments to fair value, creating large non-cash gains or losses each quarter. Heavy excise taxes, price competition, and acquisition-related costs add to the swings. That is why analysts and the company emphasize adjusted EBITDA, revenue growth, and cash position as clearer measures of underlying performance.
How can I get exposure to Organigram through an ETF?
+
OGI appears in several cannabis-focused and marijuana-sector ETFs, where it sits among other licensed producers and multi-state operators. ETF exposure spreads single-stock risk across many volatile cannabis names but dilutes how much any Organigram move affects you, and these funds can be highly volatile as a group. Always check a fund's holdings and weighting before assuming meaningful exposure to OGI specifically.
What are the main risks of investing in OGI?
+
The biggest risks are US federal cannabis prohibition, which caps the largest market, and an oversupplied, price-competitive industry with heavy excise taxes that pressure margins. Profitability has been inconsistent and reported earnings can be distorted by non-cash fair-value items. The large BAT stake concentrates ownership, future share issuance could dilute holders, and international and beverage expansion is early-stage. Cannabis stocks are also volatile and driven by regulatory sentiment.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Organigram Global Inc.'s investor relations page or your broker before making investment decisions.